Official reprint from UpToDate®
www.uptodate.com ©2015 UpToDate®

Introduction to recombinant hematopoietic growth factors

Colin A Sieff, MB, BCh, FRCPath
Section Editor
Robert S Negrin, MD
Deputy Editor
Jennifer S Tirnauer, MD


The family of glycoproteins known as the hematopoietic growth factors (HGFs) plays a major role in the proliferation, differentiation, and survival of primitive hematopoietic stem and progenitor cells, as well as in functional activation of some mature cells. These effects are mediated by high affinity binding of the HGFs to specific receptors expressed on the surface of the target cells.

The major toxicities of the HGFs, the history of their identification, and an overview of their uses will be presented here. Their uses for specific clinical indications are presented separately. (See 'Clinical uses of hematopoietic growth factors' below.)

The function of specific HGFs in the development of blood cell lineages is discussed in separate topic reviews:

Stem cell factor (see "Overview of hematopoiesis and stem cell function")

Erythropoietin (see "Regulation of erythropoiesis")


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Dec 2014. | This topic last updated: Aug 26, 2014.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2015 UpToDate, Inc.
  1. Bradley TR, Metcalf D. The growth of mouse bone marrow cells in vitro. Aust J Exp Biol Med Sci 1966; 44:287.
  2. Pluznik DH, Sachs L. The cloning of normal "mast" cells in tissue culture. J Cell Physiol 1965; 66:319.
  3. Metcalf D. Hemopoietic regulators and leukemia development: a personal retrospective. Adv Cancer Res 1994; 63:41.
  4. Clark SC, Kamen R. The human hematopoietic colony-stimulating factors. Science 1987; 236:1229.
  5. Metcalf D. The colony stimulating factors. Discovery, development, and clinical applications. Cancer 1990; 65:2185.
  6. Moore MA. Haemopoietic growth factor interactions: in vitro and in vivo preclinical evaluation. Cancer Surv 1990; 9:7.
  7. Wong GG, Clark SC. Multiple actions of interleukin 6 within a cytokine network. Immunol Today 1988; 9:137.
  8. Bazan JF. Neuropoietic cytokines in the hematopoietic fold. Neuron 1991; 7:197.
  9. Pestka S, Langer JA, Zoon KC, Samuel CE. Interferons and their actions. Annu Rev Biochem 1987; 56:727.
  10. Strober W, James SP. The interleukins. Pediatr Res 1988; 24:549.
  11. Shalaby MR, Pennica D, Palladino MA Jr. An overview of the history and biologic properties of tumor necrosis factors. Springer Semin Immunopathol 1986; 9:33.
  12. Fung MC, Hapel AJ, Ymer S, et al. Molecular cloning of cDNA for murine interleukin-3. Nature 1984; 307:233.
  13. Yokota T, Lee F, Rennick D, et al. Isolation and characterization of a mouse cDNA clone that expresses mast-cell growth-factor activity in monkey cells. Proc Natl Acad Sci U S A 1984; 81:1070.
  14. Kindler V, Thorens B, de Kossodo S, et al. Stimulation of hematopoiesis in vivo by recombinant bacterial murine interleukin 3. Proc Natl Acad Sci U S A 1986; 83:1001.
  15. Metcalf D, Begley CG, Johnson GR, et al. Effects of purified bacterially synthesized murine multi-CSF (IL-3) on hematopoiesis in normal adult mice. Blood 1986; 68:46.
  16. Donahue RE, Wang EA, Stone DK, et al. Stimulation of haematopoiesis in primates by continuous infusion of recombinant human GM-CSF. Nature 1986; 321:872.
  17. Dranoff G, Crawford AD, Sadelain M, et al. Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis. Science 1994; 264:713.
  18. Stanley E, Lieschke GJ, Grail D, et al. Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. Proc Natl Acad Sci U S A 1994; 91:5592.
  19. Lieschke GJ, Grail D, Hodgson G, et al. Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. Blood 1994; 84:1737.
  20. Welte K, Bonilla MA, Gillio AP, et al. Recombinant human granulocyte colony-stimulating factor. Effects on hematopoiesis in normal and cyclophosphamide-treated primates. J Exp Med 1987; 165:941.
  21. Sieff CA, Emerson SG, Mufson A, et al. Dependence of highly enriched human bone marrow progenitors on hemopoietic growth factors and their response to recombinant erythropoietin. J Clin Invest 1986; 77:74.
  22. Eaves CJ, Eaves AC. Erythropoietin (Ep) dose-response curves for three classes of erythroid progenitors in normal human marrow and in patients with polycythemia vera. Blood 1978; 52:1196.
  23. Arcasoy MO. The non-haematopoietic biological effects of erythropoietin. Br J Haematol 2008; 141:14.
  24. Merchionne F, Dammacco F. Biological functions and therapeutic use of erythropoiesis-stimulating agents: perplexities and perspectives. Br J Haematol 2009; 146:127.
  25. Bunn HF. New agents that stimulate erythropoiesis. Blood 2007; 109:868.
  26. Wendling F, Maraskovsky E, Debili N, et al. cMpl ligand is a humoral regulator of megakaryocytopoiesis. Nature 1994; 369:571.
  27. Souyri M, Vigon I, Penciolelli JF, et al. A putative truncated cytokine receptor gene transduced by the myeloproliferative leukemia virus immortalizes hematopoietic progenitors. Cell 1990; 63:1137.
  28. Methia N, Louache F, Vainchenker W, Wendling F. Oligodeoxynucleotides antisense to the proto-oncogene c-mpl specifically inhibit in vitro megakaryocytopoiesis. Blood 1993; 82:1395.
  29. de Sauvage FJ, Hass PE, Spencer SD, et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature 1994; 369:533.
  30. Bartley TD, Bogenberger J, Hunt P, et al. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell 1994; 77:1117.
  31. Lok S, Kaushansky K, Holly RD, et al. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature 1994; 369:565.
  32. Harker LA, Marzec UM, Hunt P, et al. Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates. Blood 1996; 88:511.
  33. Harker LA. Physiology and clinical applications of platelet growth factors. Curr Opin Hematol 1999; 6:127.
  34. Kuter DJ, Begley CG. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood 2002; 100:3457.
  35. Jenkins JM, Williams D, Deng Y, et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood 2007; 109:4739.
  36. Wang B, Nichol JL, Sullivan JT. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther 2004; 76:628.
  37. Galli SJ, Zsebo KM, Geissler EN. The kit ligand, stem cell factor. Adv Immunol 1994; 55:1.
  38. Hannum C, Culpepper J, Campbell D, et al. Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs. Nature 1994; 368:643.
  39. Lyman SD, James L, Johnson L, et al. Cloning of the human homologue of the murine flt3 ligand: a growth factor for early hematopoietic progenitor cells. Blood 1994; 83:2795.
  40. Li J, Yang C, Xia Y, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001; 98:3241.
  41. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006; 24:3187.
  42. Burris HA, Belani CP, Kaufman PA, et al. Pegfilgrastim on the Same Day Versus Next Day of Chemotherapy in Patients With Breast Cancer, Non-Small-Cell Lung Cancer, Ovarian Cancer, and Non-Hodgkin's Lymphoma: Results of Four Multicenter, Double-Blind, Randomized Phase II Studies. J Oncol Pract 2010; 6:133.
  43. Anderlini P, Champlin RE. Biologic and molecular effects of granulocyte colony-stimulating factor in healthy individuals: recent findings and current challenges. Blood 2008; 111:1767.
  44. Lyman GH, Dale DC. Long-term outcomes of myeloid growth factor treatment. J Natl Compr Canc Netw 2011; 9:945.
  45. Arnaout MA, Wang EA, Clark SC, Sieff CA. Human recombinant granulocyte-macrophage colony-stimulating factor increases cell-to-cell adhesion and surface expression of adhesion-promoting surface glycoproteins on mature granulocytes. J Clin Invest 1986; 78:597.
  46. Socinski MA, Cannistra SA, Elias A, et al. Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man. Lancet 1988; 1:1194.
  47. Devereux S, Linch DC, Campos Costa D, et al. Transient leucopenia induced by granulocyte-macrophage colony-stimulating factor. Lancet 1987; 2:1523.
  48. Johnson ML, Grimwood RE. Leukocyte colony-stimulating factors. A review of associated neutrophilic dermatoses and vasculitides. Arch Dermatol 1994; 130:77.
  49. Glaspy JA, Baldwin GC, Robertson PA, et al. Therapy for neutropenia in hairy cell leukemia with recombinant human granulocyte colony-stimulating factor. Ann Intern Med 1988; 109:789.
  50. Pietsch T, Bührer C, Mempel K, et al. Blood mononuclear cells from patients with severe congenital neutropenia are capable of producing granulocyte colony-stimulating factor. Blood 1991; 77:1234.
  51. Welte K, Zeidler C, Reiter A, et al. Differential effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in children with severe congenital neutropenia. Blood 1990; 75:1056.
  52. Bidyasar S, Montoya M, Suleman K, Markowitz AB. Sweet syndrome associated with granulocyte colony-stimulating factor. J Clin Oncol 2008; 26:4355.
  53. Antman KS, Griffin JD, Elias A, et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med 1988; 319:593.
  54. Brandt SJ, Peters WP, Atwater SK, et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. N Engl J Med 1988; 318:869.
  55. Shpall EJ. The utilization of cytokines in stem cell mobilization strategies. Bone Marrow Transplant 1999; 23 Suppl 2:S13.
  56. Costa JJ, Demetri GD, Harrist TJ, et al. Recombinant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivo. J Exp Med 1996; 183:2681.
  57. Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 2007; 25:3158.
  58. Gregory SA, Schwartzberg LS, Mo M, et, al. Evaluation of reported bone pain in cancer patients receiving chemotherapy in pegfilgrastim clinical trials: a retrospective analysis. Commun Oncol 2010; 7:297.
  59. Tigue CC, McKoy JM, Evens AM, et al. Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project. Bone Marrow Transplant 2007; 40:185.
  60. Pulsipher MA, Chitphakdithai P, Miller JP, et al. Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program. Blood 2009; 113:3604.
  61. Lambertini M, Del Mastro L, Bellodi A, Pronzato P. The five "Ws" for bone pain due to the administration of granulocyte-colony stimulating factors (G-CSFs). Crit Rev Oncol Hematol 2014; 89:112.
  62. Kirshner JJ, Heckler CE, Janelsins MC, et al. Prevention of pegfilgrastim-induced bone pain: a phase III double-blind placebo-controlled randomized clinical trial of the university of rochester cancer center clinical community oncology program research base. J Clin Oncol 2012; 30:1974.
  63. Gribben JG, Devereux S, Thomas NS, et al. Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF. Lancet 1990; 335:434.
  64. Vadhan-Raj S, Murray LJ, Bueso-Ramos C, et al. Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Ann Intern Med 1997; 126:673.
  65. Goodnough LT, Dipersio J, Mccullough J, et al. Transfusion 1997; 37 Suppl 9S:67S.
  66. Touw IP, Bontenbal M. Granulocyte colony-stimulating factor: key (f)actor or innocent bystander in the development of secondary myeloid malignancy? J Natl Cancer Inst 2007; 99:183.
  67. Pamphilon D, Nacheva E, Navarrete C, et al. The use of granulocyte-colony-stimulating factor in volunteer unrelated hemopoietic stem cell donors. Transfusion 2008; 48:1495.
  68. Beekman R, Touw IP. G-CSF and its receptor in myeloid malignancy. Blood 2010; 115:5131.
  69. Welte K, Boxer LA. Severe chronic neutropenia: pathophysiology and therapy. Semin Hematol 1997; 34:267.
  70. Smith OP, Reeves BR, Kempski HM, Evans JP. Kostmann's disease, recombinant HuG-CSF, monosomy 7 and MDS/AML. Br J Haematol 1995; 91:150.
  71. Ohara A, Kojima S, Hamajima N, et al. Myelodysplastic syndrome and acute myelogenous leukemia as a late clonal complication in children with acquired aplastic anemia. Blood 1997; 90:1009.
  72. Hashino S, Imamura M, Tanaka J, et al. Transformation of severe aplastic anemia into acute myeloblastic leukemia with monosomy 7. Ann Hematol 1996; 72:337.
  73. Kaito K, Kobayashi M, Katayama T, et al. Long-term administration of G-CSF for aplastic anaemia is closely related to the early evolution of monosomy 7 MDS in adults. Br J Haematol 1998; 103:297.
  74. Lyman GH, Dale DC, Wolff DA, et al. Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. J Clin Oncol 2010; 28:2914.
  75. Koyanagi Y, O'Brien WA, Zhao JQ, et al. Cytokines alter production of HIV-1 from primary mononuclear phagocytes. Science 1988; 241:1673.
  76. Wang J, Roderiquez G, Oravecz T, Norcross MA. Cytokine regulation of human immunodeficiency virus type 1 entry and replication in human monocytes/macrophages through modulation of CCR5 expression. J Virol 1998; 72:7642.
  77. Bennett WM. A multicenter clinical trial of epoetin beta for anemia of end-stage renal disease. J Am Soc Nephrol 1991; 1:990.
  78. Eschbach JW, Abdulhadi MH, Browne JK, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med 1989; 111:992.
  79. Buur T, Lundberg M. Secondary effects of erythropoietin treatment on metabolism and dialysis efficiency in stable hemodialysis patients. Clin Nephrol 1990; 34:230.
  80. Edmunds ME, Walls J, Tucker B, et al. Seizures in haemodialysis patients treated with recombinant human erythropoietin. Nephrol Dial Transplant 1989; 4:1065.
  81. Raine AE, Roger SD. Effects of erythropoietin on blood pressure. Am J Kidney Dis 1991; 18:76.
  82. Abraham PA, Macres MG. Blood pressure in hemodialysis patients during amelioration of anemia with erythropoietin. J Am Soc Nephrol 1991; 2:927.
  83. Watson AJ, Gimenez LF, Cotton S, et al. Treatment of the anemia of chronic renal failure with subcutaneous recombinant human erythropoietin. Am J Med 1990; 89:432.
  84. Kang DH, Yoon KI, Han DS. Acute effects of recombinant human erythropoietin on plasma levels of proendothelin-1 and endothelin-1 in haemodialysis patients. Nephrol Dial Transplant 1998; 13:2877.
  85. Kaupke CJ, Kim S, Vaziri ND. Effect of erythrocyte mass on arterial blood pressure in dialysis patients receiving maintenance erythropoietin therapy. J Am Soc Nephrol 1994; 4:1874.
  86. Feagan BG, Wong CJ, Kirkley A, et al. Erythropoietin with iron supplementation to prevent allogeneic blood transfusion in total hip joint arthroplasty. A randomized, controlled trial. Ann Intern Med 2000; 133:845.
  87. Dale DC. Neutrophil biology and the next generation of myeloid growth factors. J Natl Compr Canc Netw 2009; 7:92.
  88. Papayannopoulou T, Nakamoto B. Peripheralization of hemopoietic progenitors in primates treated with anti-VLA4 integrin. Proc Natl Acad Sci U S A 1993; 90:9374.
  89. Papayannopoulou T, Craddock C, Nakamoto B, et al. The VLA4/VCAM-1 adhesion pathway defines contrasting mechanisms of lodgement of transplanted murine hemopoietic progenitors between bone marrow and spleen. Proc Natl Acad Sci U S A 1995; 92:9647.
  90. Craddock CF, Nakamoto B, Andrews RG, et al. Antibodies to VLA4 integrin mobilize long-term repopulating cells and augment cytokine-induced mobilization in primates and mice. Blood 1997; 90:4779.
  91. Papayannopoulou T, Priestley GV, Nakamoto B. Anti-VLA4/VCAM-1-induced mobilization requires cooperative signaling through the kit/mkit ligand pathway. Blood 1998; 91:2231.
  92. Sauvageau G, Thorsteinsdottir U, Eaves CJ, et al. Overexpression of HOXB4 in hematopoietic cells causes the selective expansion of more primitive populations in vitro and in vivo. Genes Dev 1995; 9:1753.
  93. Macdougall IC, Eckardt KU. Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia. Lancet 2006; 368:947.
  94. Liu Z, Stoll VS, Devries PJ, et al. A potent erythropoietin-mimicking human antibody interacts through a novel binding site. Blood 2007; 110:2408.
  95. Livnah O, Stura EA, Johnson DL, et al. Functional mimicry of a protein hormone by a peptide agonist: the EPO receptor complex at 2.8 A. Science 1996; 273:464.
  96. Wrighton NC, Farrell FX, Chang R, et al. Small peptides as potent mimetics of the protein hormone erythropoietin. Science 1996; 273:458.
  97. Johnson DL, Farrell FX, Barbone FP, et al. Identification of a 13 amino acid peptide mimetic of erythropoietin and description of amino acids critical for the mimetic activity of EMP1. Biochemistry 1998; 37:3699.
  98. Livnah O, Stura EA, Middleton SA, et al. Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation. Science 1999; 283:987.
  99. Johnson DL, Farrell FX, Barbone FP, et al. Amino-terminal dimerization of an erythropoietin mimetic peptide results in increased erythropoietic activity. Chem Biol 1997; 4:939.
  100. Stead RB, Lambert J, Wessels D, et al. Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers. Blood 2006; 108:1830.
  101. http://www.takeda.com/news/2013/20130701_5854.html (Accessed on February 12, 2014).
  102. Osterborg A, Steegmann JL, Hellmann A, et al. Phase II study of three dose levels of continuous erythropoietin receptor activator (C.E.R.A.) in anaemic patients with aggressive non-Hodgkin's lymphoma receiving combination chemotherapy. Br J Haematol 2007; 136:736.
  103. Hsieh MM, Linde NS, Wynter A, et al. HIF prolyl hydroxylase inhibition results in endogenous erythropoietin induction, erythrocytosis, and modest fetal hemoglobin expression in rhesus macaques. Blood 2007; 110:2140.
  104. Bernhardt WM, Wiesener MS, Scigalla P, et al. Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J Am Soc Nephrol 2010; 21:2151.
  105. Maiese K, Li F, Chong ZZ. New avenues of exploration for erythropoietin. JAMA 2005; 293:90.